A California jury on [November 14, 2018] cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company’s talc-based products, including its baby powder, contain asbestos and caused her cancer, the company said. The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen … [Read more...]
Differentiating epithelioid mesothelioma from lung adenocarcinoma — MUC21 is a novel, negative immunohistochemical marker
A recent medical study investigated the potential usefulness of mucin 21 (MUC21), as a novel, negative diagnostic marker for purpose of differentiating epithelioid mesothelioma from lung adenocarcinoma. In order to analyze the expression of MUC21 by immunohistochemistry, 70 epithelioid mesothelioma and 70 lung adenocarcinoma cases were examined. … [Read more...]
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer (NCT02414269). Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 … [Read more...]
Current treatments and trials in malignant pleural mesothelioma
Objectives This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress. Results Since the original trial that demonstrated the efficacy of pemetrexed and cisplatin in mesothelioma, multiple trials have been conducted that have … [Read more...]
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
We generated a comprehensive atlas of the immunologic cellular networks within human malignant pleural mesothelioma (MPM) using mass cytometry. Data-driven analyses of these high-resolution single-cell data identified 2 distinct immunologic subtypes of MPM with vastly different cellular composition, activation states, and immunologic function; mass … [Read more...]
J&J Must Pay Millions Over Banker’s Baby Powder Cancer Claim
Johnson & Johnson and a talc mining company must pay at least $37 million to an investment banker who blamed the companies’ products for causing him to develop a deadly cancer linked to asbestos. Jurors in state court in New Brunswick, New Jersey concluded Thursday J&J and Imerys SA hid that their talc-based products, including J&J’s … [Read more...]
J&J Jury Set to Weigh Banker’s Claims Baby Powder Caused Cancer
Jurors are set to weigh an investment banker’s claims that using Johnson & Johnson’s baby powder for more than 30 years caused him to develop a deadly cancer linked to asbestos. A New Jersey jury will begin deciding Wednesday whether Stephen Lanzo III can legitimately blame J&J’s iconic product for his mesothelioma, an often-fatal cancer … [Read more...]
Immunotherapy Making Headway in SCLC and Mesothelioma
Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD. The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, … [Read more...]
Past and current asbestos exposure and future mesothelioma risks in Britain: The Inhaled Particles Study (TIPS)
Background: Occupational and environmental airborne asbestos concentrations are too low and variable for lifetime exposures to be estimated reliably, and building workers and occupants may suffer higher exposure when asbestos in older buildings is disturbed or removed. Mesothelioma risks from current asbestos exposures are therefore not … [Read more...]
Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial
Background: The SMART trial is a UK-based, multicentre RCT comparing prophylactic radiotherapy and symptom-based (deferred) radiotherapy in 203 patients with Malignant Pleural Mesothelioma who had undergone large bore pleural interventions. Using costs and quality of life data collected alongside the clinical trial, we will estimate the … [Read more...]